Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PRLD |
---|---|---|
09:32 ET | 524 | 2.02 |
09:39 ET | 100 | 1.99 |
09:41 ET | 1400 | 1.99 |
09:43 ET | 2200 | 2 |
09:45 ET | 100 | 1.9899 |
09:48 ET | 1100 | 2 |
09:50 ET | 700 | 2.01 |
09:52 ET | 410 | 2.01 |
09:54 ET | 800 | 2.02 |
09:56 ET | 100 | 2.02 |
09:59 ET | 200 | 2.02 |
10:03 ET | 1400 | 2.02 |
10:06 ET | 387 | 2.02 |
10:08 ET | 100 | 2.02 |
10:10 ET | 100 | 2.02 |
10:12 ET | 200 | 2.02 |
10:15 ET | 300 | 2.02 |
10:17 ET | 200 | 2 |
10:19 ET | 100 | 1.99 |
10:21 ET | 250 | 2.0069 |
10:24 ET | 6271 | 1.98 |
10:28 ET | 100 | 1.97 |
10:30 ET | 100 | 1.98 |
10:33 ET | 100 | 2 |
10:35 ET | 100 | 2 |
10:37 ET | 100 | 1.995 |
10:46 ET | 100 | 1.995 |
10:50 ET | 100 | 2 |
10:53 ET | 200 | 2.01 |
10:55 ET | 1010 | 1.985 |
10:57 ET | 2212 | 1.95 |
11:00 ET | 1420 | 1.945 |
11:02 ET | 200 | 1.946 |
11:04 ET | 1800 | 1.97 |
11:06 ET | 100 | 1.97 |
11:09 ET | 700 | 1.96 |
11:18 ET | 400 | 1.97 |
11:22 ET | 100 | 1.98 |
11:24 ET | 100 | 1.975 |
11:26 ET | 1700 | 1.96 |
11:27 ET | 100 | 1.95 |
11:29 ET | 100 | 1.945 |
11:33 ET | 600 | 1.96 |
11:44 ET | 100 | 1.97 |
11:45 ET | 200 | 1.97 |
11:49 ET | 200 | 1.97 |
11:51 ET | 600 | 1.96 |
11:54 ET | 300 | 1.96 |
11:58 ET | 300 | 1.96 |
12:00 ET | 100 | 1.965 |
12:14 ET | 300 | 1.97 |
12:20 ET | 100 | 1.98 |
12:23 ET | 200 | 1.98 |
12:25 ET | 100 | 1.98 |
12:27 ET | 458 | 1.98 |
12:30 ET | 100 | 1.985 |
12:32 ET | 500 | 1.98 |
12:36 ET | 5100 | 1.96 |
12:39 ET | 200 | 1.96 |
12:41 ET | 100 | 1.96 |
12:43 ET | 100 | 1.97 |
12:45 ET | 300 | 1.97 |
12:48 ET | 498 | 1.97 |
12:52 ET | 1200 | 1.98 |
12:54 ET | 100 | 1.98 |
12:56 ET | 1267 | 1.985 |
12:57 ET | 700 | 1.98 |
01:03 ET | 100 | 1.96 |
01:10 ET | 300 | 1.96 |
01:12 ET | 700 | 1.96 |
01:15 ET | 302 | 1.97 |
01:17 ET | 100 | 1.97 |
01:26 ET | 100 | 1.985 |
01:28 ET | 100 | 1.99 |
01:30 ET | 100 | 1.99 |
01:32 ET | 300 | 1.99 |
01:37 ET | 733 | 1.98 |
01:46 ET | 986 | 1.99 |
01:50 ET | 200 | 1.9999 |
01:55 ET | 900 | 2 |
02:00 ET | 200 | 2 |
02:06 ET | 200 | 1.995 |
02:08 ET | 388 | 1.99 |
02:09 ET | 659 | 1.986 |
02:11 ET | 300 | 1.99 |
02:13 ET | 100 | 1.99 |
02:18 ET | 350 | 2 |
02:22 ET | 100 | 1.995 |
02:24 ET | 100 | 2 |
02:26 ET | 100 | 2 |
02:27 ET | 100 | 2 |
02:29 ET | 1000 | 1.99 |
02:31 ET | 200 | 1.995 |
02:36 ET | 200 | 1.995 |
02:44 ET | 100 | 2 |
02:47 ET | 200 | 1.995 |
02:49 ET | 400 | 2 |
02:56 ET | 100 | 2 |
02:58 ET | 299 | 1.99 |
03:00 ET | 100 | 2 |
03:02 ET | 100 | 2 |
03:03 ET | 100 | 2 |
03:05 ET | 100 | 2 |
03:07 ET | 100 | 2 |
03:09 ET | 100 | 2 |
03:12 ET | 100 | 2 |
03:14 ET | 100 | 2 |
03:16 ET | 2059 | 1.99 |
03:23 ET | 100 | 2 |
03:25 ET | 200 | 2 |
03:32 ET | 100 | 2 |
03:34 ET | 200 | 1.995 |
03:36 ET | 200 | 1.99 |
03:38 ET | 100 | 1.995 |
03:39 ET | 200 | 2 |
03:41 ET | 200 | 2 |
03:43 ET | 400 | 1.995 |
03:45 ET | 100 | 2 |
03:48 ET | 200 | 1.995 |
03:50 ET | 936 | 2.005 |
03:52 ET | 4428 | 2.03 |
03:54 ET | 5907 | 2.03 |
03:56 ET | 2773 | 2.03 |
03:57 ET | 300 | 2.025 |
03:59 ET | 60492 | 2.03 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Prelude Therapeutics Inc | 111.7M | -1.1x | --- |
Skye Bioscience Inc | 111.9M | -0.9x | --- |
Verastem Inc | 113.5M | -0.9x | --- |
Fractyl Health Inc | 110.5M | -1.7x | --- |
Invivyd Inc | 107.5M | -0.5x | --- |
Benitec Biopharma Inc | 115.8M | -1.0x | --- |
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $111.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 55.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.47 |
EPS | $-1.80 |
Book Value | $5.64 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.